Summary: In a secondary analysis of a randomised trial in type 2 diabetes, probiotics plus omega-3 fatty acids improved beta-cell function only marginally versus baseline and not significantly versus placebo once adjusted, though several secondary metabolic markers did improve.
PICO Summary
| Element | Detail |
|---|---|
| Population | 45 adults with type 2 diabetes and beta-cell dysfunction (%B <50%) on insulin with or without oral agents; secondary analysis of an RCT, Ukraine. |
| Intervention | Live multistrain probiotic plus high-dose omega-3 polyunsaturated fatty acids. |
| Comparison | Placebo. |
| Outcome | Beta-cell function (%B) rose from 42.2 to 62.2, but this was only marginally significant versus baseline (p=0.049) and was not significant versus placebo in adjusted ANCOVA. Placebo changed little. Secondary outcomes improved: lower fasting glucose and TNF-α, better anthropometrics, and improved insulin sensitivity. |
Probiotic + omega-3 PUFAs and beta-cell function in T2D
RCT secondary analysis · type 2 diabetes
Beta-cell function rose within the active group only marginally and was not significant versus placebo after adjustment. The primary endpoint was not met; secondary metabolic markers improved.
Expert Commentary
This study needs careful reading, because the headline question, whether the supplement improves beta-cell function, is best answered no rather than yes on the primary endpoint. The apparent within-group rise in %B was only marginally significant against baseline at p=0.049, and crucially it did not reach significance versus placebo once the analysis was adjusted, which is the comparison that actually tests the intervention. Presenting this as a significant improvement over placebo would misstate the result. What is more defensible is the pattern of secondary outcomes, lower fasting glucose, reduced TNF-α, better anthropometrics, and improved insulin sensitivity, which is biologically coherent given probiotics and omega-3 fatty acids plausibly act on inflammation and insulin resistance rather than on islet regeneration. Even these, though, are secondary and hypothesis-generating in a small sample of 45 analysed as a secondary analysis. Can I use this with my patients? Not as a beta-cell therapy. I would not present this combination as a way to restore islet function, and at most I might view it as a low-risk adjunct with possible metabolic benefits on insulin sensitivity, while being clear with patients that the primary outcome was not met and that proven glucose-lowering therapy remains the priority.
References
Savytska M, Kyriienko D, Mykhalchyshyn G, Tsyryuk O, Falalyeyeva T, Kobyliak N. Efficacy of probiotic co-supplementation with omega-3 PUFAs on pancreatic beta-cell function in type 2 diabetes. Sci Rep. 2025;15(1):33870. doi:10.1038/s41598-025-07861-2